Introduction

Biosafety and human genetic resources management are important compliance areas that pharmaceutical companies need to pay attention to when conducting R&D, clinical trials, biologics production and cross-border scientific research cooperation. Relevant activities may simultaneously involve regulatory requirements such as the safety of biotechnology research and development, pathogenic microorganism laboratory management, and the protection and utilization of human genetic resources. Companies should identify the applicable regulatory rules based on the research content, biological materials and data types, participating entities and cross-border arrangements, and implement the corresponding requirements into project implementation and day-to-day management.

Under the Biosecurity Law, biosafety means that the State effectively prevents and responds to threats from dangerous biological factors and related factors, biotechnology can develop in a stable and healthy manner, people's life and health and the ecosystem are relatively free from danger and threats, and the biological field has the capacity to safeguard national security and sustainable development. The protection and utilization of human genetic resources is an important component of biosafety regulation, relating both to medical research and the development of the biopharmaceutical industry, and also to public health, national security and public interests.

Human genetic resources include human genetic resource materials and human genetic resource information. Among them, human genetic resource materials refer to genetic materials such as organs, tissues and cells that contain the human genome, genes and other genetic material; human genetic resource information refers to data and other information materials generated by using human genetic resource materials. Therefore, compliance management of human genetic resources by pharmaceutical companies should cover the processing activities of relevant materials and information, and the applicable regulatory requirements should be determined according to the nature of the specific activities.

Based on the main business scenarios of pharmaceutical companies, this article introduces the legal norms and regulatory authorities in the fields of biosafety and human genetic resources, focuses on analyzing compliance issues such as administrative licensing, filing and prior reporting for human genetic resources, entry and exit of biological materials, processing of relevant data and foreign investment, and illustrates the relevant legal risks and management measures that companies should take through typical cases.

China's biosafety regulation covers areas such as the prevention and control of major emerging and sudden infectious diseases and animal and plant epidemics, biotechnology research, development and application, pathogenic microorganism laboratory management, protection of human genetic resources and biological resources, prevention of invasive alien species, response to microbial resistance, and prevention of bioterrorism and biological weapons threats. The Biosecurity Law sets out comprehensive provisions on the basic principles, risk prevention and control systems, subject obligations and legal liabilities in the relevant fields; laws such as the Law on the Prevention and Control of Infectious Diseases, the Drug Administration Law, the Vaccine Administration Law and the Frontier Health Quarantine Law regulate biosafety-related activities from the perspectives of disease prevention and control, drug and vaccine safety, and frontier health quarantine, respectively.

At the level of administrative regulations, the Regulations on the Biosafety Management of Pathogenic Microorganism Laboratories, the Regulations on the Management of Human Genetic Resources, the Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies and others set out specific provisions on the regulatory objects, implementation conditions and management procedures in specific fields, and the relevant departmental rules, normative documents and technical standards further clarify operational requirements. In addition, where personal rights and interests, personal information and data processing, damages compensation or criminal offenses are involved, the relevant provisions of the Civil Code, the Personal Information Protection Law, the Data Security Law, the Criminal Law and other laws shall also apply.

For pharmaceutical companies, the same R&D or clinical research project may simultaneously be subject to multiple institutional constraints. Companies should identify the applicable norms according to the specific activities, distinguish the applicable conditions of different licensing, filing, ethical review and safety management procedures, and perform the corresponding obligations separately.

1. The Biosecurity Law

The Biosecurity Law was adopted on October 17, 2020, came into force on April 15, 2021, and was amended on April 26, 2024. The 2024 amendment mainly aligns with the division of responsibilities after institutional reform, adjusting the competent authorities in provisions on human genetic resources surveys, relevant approvals, prior reporting of information provided abroad and relevant administrative penalties to the competent health department of the State Council (i.e., the National Health Commission), and correspondingly adjusting the departmental division of responsibilities for biological resources surveys.

The Biosecurity Law consists of ten chapters and eighty-eight articles and is the foundational and comprehensive law in China's biosafety field. The Law establishes systems such as risk monitoring and early warning, investigation and assessment, information sharing and release, catalogue and list management, biosafety review, emergency response and supervision and inspection, and sets out specific management requirements for fields such as biotechnology research and development, pathogenic microorganism laboratories, human genetic resources and biological resources. That the State enjoys sovereignty over China's human genetic resources and biological resources is also a basic rule explicitly established by the Law.

The Biosecurity Law contains both institutional provisions that require further refinement by supporting norms and directly stipulates the obligations and prohibitive requirements that relevant units and individuals should perform. For example, units engaged in biotechnology research, development and application activities shall be responsible for the safety of the relevant activities of their own units; the establishing units of pathogenic microorganism laboratories bear the responsibility for laboratory biosafety management, and their legal representatives and laboratory heads are responsible for the biosafety of the laboratories. Therefore, companies should implement the subject responsibilities established by the Law and relevant supporting norms in light of their specific business.

The main contents of the Law and the regulatory requirements relevant to pharmaceutical companies are as follows:

Under the above institutional framework, pharmaceutical companies should focus on the subject qualifications, implementation conditions, approval and filing, and whole-process management requirements involved in biotechnology research and development, pathogenic microorganism laboratories and human genetic resource activities. The specific application of the relevant systems also needs to be determined in light of the specialized legal norms described below and the current provisions of the competent authorities.

Around the basic institutional framework established by the Biosecurity Law, China has formed a corresponding system of specialized legal norms for different types of biosafety risks. First, in the fields of biotechnology research, clinical translation and pathogenic microorganism laboratory safety, the Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies, the Regulations on the Biosafety Management of Pathogenic Microorganism Laboratories, the Measures for the Administration of Collection Institutions of Pathogenic Microorganism Strains (Viruses) Infectious to Humans and others set out specific provisions on clinical research and clinical translation and application of new biomedical technologies, pathogenic microorganism laboratory activities and the management of relevant biological materials, respectively; second, in the field of biologics regulation, the Drug Administration Law, the Vaccine Administration Law, the Implementing Regulations of the Drug Administration Law, the Measures for the Administration of Batch Release of Biological Products and others regulate the development, production, operation and use of biological products; third, in the field of protection and utilization of human genetic resources, the Regulations on the Management of Human Genetic Resources and their implementing rules and other norms set out specialized provisions on activities such as the collection, preservation, utilization and provision abroad of human genetic resources; fourth, in the fields of infectious disease prevention and control, frontier health quarantine and export control of biological items, laws and regulations such as the Law on the Prevention and Control of Infectious Diseases, the Frontier Health Quarantine Law and the Regulations on Export Control of Dual-Use Items also constitute important components of the biosafety regulatory system. The following provides a specific introduction in light of the fields more closely related to the R&D, production and clinical research activities of pharmaceutical companies.

(1) Safety Management of Biotechnology Research, Clinical Translation and Pathogenic Microorganism Laboratories

Biotechnology research, development and application and related laboratory activities are important links in pharmaceutical R&D and biopharmaceutical manufacturing, and their safety management is directly related to the compliant conduct of R&D activities. Chapter IV of the Biosecurity Law sets out specialized provisions on the safety of biotechnology research, development and application, establishing basic systems such as classified management of biosafety risks, process management, traceability management of important equipment and special biological factors, and ethical review of clinical research on new biomedical technologies.

It is worth noting that, under the Biosecurity Law, units engaged in biotechnology research, development and application activities shall be responsible for the safety of the relevant activities of their own units, and shall adopt biosafety risk prevention and control measures and establish systems such as biosafety training, follow-up inspection and periodic reporting. The State implements classified management of high-risk, medium-risk and low-risk biotechnology research and development activities according to the degree of risk that the relevant activities pose to public health, industry and agriculture, the ecological environment and others. Engaging in high-risk and medium-risk biotechnology research and development activities shall be carried out by legal person organizations lawfully established within the territory of China, and approval shall be obtained or filing made in accordance with the law, while risk assessments shall be conducted, risk prevention and control plans formulated and biosafety incident emergency plans prepared.

For important equipment and special biological factors involving biosafety, the Biosecurity Law implements traceability management. The purchase or introduction of important equipment and special biological factors included in the control list shall be registered in accordance with the law, ensure traceability, and be filed in accordance with the provisions.

With respect to clinical research and clinical translation and application of new biomedical technologies, the Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies came into force on May 1, 2026, and, on the basis of the principled provisions of the Biosecurity Law, further set out provisions on clinical research, clinical translation and application of new biomedical technologies and their supervision and management.

Under the Regulations, before conducting clinical research on new biomedical technologies, non-clinical research such as laboratory research and animal experiments shall be conducted in accordance with the law; clinical research may be conducted only after the non-clinical research proves that the technology is safe and effective and after passing academic review and ethical review. Clinical research institutions shall file with the health department of the State Council within 5 working days from the date of passing academic review and ethical review. Where it is intended to translate the relevant new biomedical technology into clinical application after the completion of clinical research, the clinical translation and application approval procedures shall be performed in accordance with the law.

It should be noted that there is a clear institutional linkage between the regulatory pathway for new biomedical technologies and the regulatory pathways for drugs and medical devices. Under the Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies and the relevant implementation requirements, where clinical trials are conducted for the development of drugs or medical devices, the relevant regulatory provisions for drugs and medical devices shall apply. Relevant R&D entities should reasonably determine whether the regulatory pathway for new biomedical technologies or the regulatory pathway for drugs and medical devices applies, in light of the technical attributes, research purposes and intended translation and application methods, and perform the corresponding filing, clinical trial and review and approval procedures accordingly.

With respect to the safety management of pathogenic microorganism laboratories, the Regulations on the Biosafety Management of Pathogenic Microorganism Laboratories set out specific provisions on the classification of pathogenic microorganisms, the grading of laboratories, experimental activities involving highly pathogenic microorganisms, and the collection, transport and preservation of strains (viruses) and samples. The Regulations were revised again in December 2024, and the relevant provisions on the construction review of high-level pathogenic microorganism laboratories were correspondingly amended in line with the adjustment of regulatory responsibilities. From January 20, 2025, the construction review of high-level pathogenic microorganism laboratories is undertaken by the National Health Commission.

(2) Safety Regulation of Biological Products

Biological products refer to preparations made from starting materials such as microorganisms, cells, animal or human-derived tissues and body fluids, produced through biological technologies, and used for the prevention, treatment and diagnosis of human diseases. Under the current registration management rules, biological products mainly include biological products for prevention, biological products for treatment, and in vitro diagnostic reagents managed as biological products.

Under the Drug Administration Law, biological products fall within the scope of drug regulation, and their research and development, production, operation and use are first subject to the general provisions on drug regulation. At the same time, considering that biological products have particular characteristics in production processes, quality control and risk management, the Vaccine Administration Law, the appendix on biological products to the Good Manufacturing Practice for Drugs, the Measures for the Administration of Batch Release of Biological Products, the Requirements for Registration Classification and Application Dossiers of Biological Products and other rules further set out special provisions on the registration, production and post-marketing regulation of different types of biological products. The revised Implementing Regulations of the Drug Administration Law were promulgated on 16 January 2026 and came into force on 15 May 2026, further improving the regulatory systems relating to drug research and development, registration, production and the responsibilities of marketing authorization holders.

In recent years, regulation of entrusted drug production has been continuously strengthened. In 2023, the National Medical Products Administration issued the Announcement on Strengthening the Supervision and Administration of Entrusted Production by Drug Marketing Authorization Holders (No. 132 of 2023), further strengthening the licensing management, quality management system construction and implementation of primary responsibilities in entrusted production by drug marketing authorization holders, and encouraging biological product holders to have in-house production capacity. Subsequently, the Announcement on Strengthening the Supervision and Administration of Entrusted Production by Contracted Manufacturers (No. 134 of 2025) further clarified the responsibilities of contracted manufacturers in quality management, technology transfer, assessment of contracted products and management of entrusted production.

Biological product companies adopting the entrusted production model should, in light of the risk characteristics of their products, improve the quality management and supervision mechanisms between the principal and the contractor to ensure that the entire entrusted production process complies with drug production quality management requirements. For biological products subject to special regulatory requirements, such as vaccines and blood products, the corresponding special management provisions should also apply.

(3) Protection and utilization of human genetic resources

Human genetic resources are an important area of biosecurity regulation. The Biosecurity Law clarifies that the State enjoys sovereignty over China's human genetic resources and biological resources, and requires the State to strengthen the management and supervision of activities such as the collection, preservation, utilization and provision abroad of human genetic resources. The Regulations on the Administration of Human Genetic Resources and their implementing rules further establish specific administrative management systems for human genetic resources on this basis.

The current regulatory system for human genetic resources mainly includes four categories of administrative licensing—collection, preservation, international scientific research cooperation, and export of human genetic resource materials—as well as systems such as the filing of international cooperative clinical trials and prior reporting for the provision abroad or open use of human genetic resource information.

After the 2024 revision of the Regulations on the Administration of Human Genetic Resources, responsibility for national human genetic resources management was transferred from the Ministry of Science and Technology of the State Council to the competent health department of the State Council, and since 1 May 2024 the National Health Commission has undertaken the relevant management work.

With respect to legal liability for illegal acts concerning human genetic resources, the Biosecurity Law and the Regulations on the Administration of Human Genetic Resources together constitute a relatively strict administrative liability system. Under the Biosecurity Law, collecting or preserving China's human genetic resources without approval, or using China's human genetic resources to carry out international scientific research cooperation, may result in administrative liability such as being ordered to stop the illegal act, confiscation of illegal gains and of the illegally collected or preserved human genetic resources, and imposition of fines; where the circumstances are serious, the responsible persons may also be prohibited by law from engaging in the corresponding activities for a certain period.

For foreign organizations, individuals and institutions established or actually controlled by them that illegally collect or preserve China's human genetic resources within China, or provide China's human genetic resources abroad, the Biosecurity Law provides for stricter legal liability.

The Regulations on the Administration of Human Genetic Resources, in turn, provide corresponding administrative liability for collecting, preserving or carrying out international scientific research cooperation without permission, and for acts violating the requirements on filing of international cooperative clinical trials and management of human genetic resource information; where the illegal acts are serious or particularly serious, measures such as prohibiting the relevant entities and responsible persons from engaging in human genetic resources-related activities for a certain period or even permanently may also be taken in accordance with law.

As for criminal liability, the Amendment (XI) to the Criminal Law added the crime of illegally collecting human genetic resources and smuggling human genetic resource materials in Article 334A of the Criminal Law. Where, in violation of relevant State provisions, a person illegally collects China's human genetic resources or illegally transports, mails or carries China's human genetic resource materials out of the country, endangering public health or the public interest, and the act reaches the statutory threshold of seriousness, the person may bear criminal liability in accordance with law; where the circumstances are particularly serious, a higher statutory penalty applies.

In addition, in March 2025 the National Health Commission issued service guidelines for administrative licensing matters concerning human genetic resources, and the scope and procedures for filing and prior reporting, and during 2025 successively issued several batches of frequently asked questions on human genetic resources management, providing further explanations on matters such as the relationship between the application of collection and preservation licenses, the connection between international scientific research cooperation licenses and filing of international cooperative clinical trials, the determination of substantive participation by foreign entities, the specific scope of human genetic resource materials, and the provision abroad or open use of human genetic resource information. In addition to determining their statutory obligations under the Regulations on the Administration of Human Genetic Resources and their implementing rules, relevant companies should also, in light of the current service guidelines and the publicly disclosed regulatory positions of the competent authorities, conduct specific analysis of factors such as the sample types, research purposes, cooperating parties, data flows and material export involved in a specific project.

It is worth noting that in May 2026 the National Health Commission publicly solicited comments on the revision of the Implementing Rules of the Regulations on the Administration of Human Genetic Resources. As of the date of finalization of this article, the revised implementing rules have not yet been officially promulgated and put into effect, and at this stage compliance determinations should still be based on the currently effective Implementing Rules of the Regulations on the Administration of Human Genetic Resources and the relevant currently effective regulatory provisions.

(2) Main regulatory authorities for biosecurity and human genetic resources

1. Health authorities (National Health Commission)

The National Health Commission undertakes multiple regulatory responsibilities in the health field within the current biosecurity regulatory system. The Regulations on the Administration of Human Genetic Resources as revised in 2024 clarify that the competent health department of the State Council is responsible for national human genetic resources management. Since 1 May 2024, the human genetic resources management responsibilities formerly undertaken by the Ministry of Science and Technology have been transferred to the National Health Commission.

At present, the National Health Commission undertakes, in accordance with law, work relating to administrative licensing, filing, prior reporting and supervision and management of human genetic resources, and the competent human genetic resources departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government are responsible for the relevant human genetic resources management work within their respective administrative regions.

In addition, the National Health Commission also undertakes, in accordance with law, responsibilities such as supervision and management of clinical research and clinical translation and application of new biomedical technologies, and review of the construction of high-level pathogenic microorganism laboratories. The National Disease Control and Prevention Administration, as a national administration managed by the National Health Commission, mainly undertakes responsibilities such as infectious disease prevention and control, monitoring and early warning, the national immunization program, and public health supervision.

2. Science and technology administrative department (Ministry of Science and Technology)

The Ministry of Science and Technology mainly undertakes relevant regulatory responsibilities in areas such as the safety of biotechnology research and development. Under the Biosecurity Law, the risk classification standards and catalogues for biotechnology research and development activities are formulated, adjusted and published by the competent departments of the State Council for science and technology, health, agriculture and rural affairs, etc., according to the division of responsibilities, together with other relevant departments of the State Council.

The currently effective Measures for the Administration of the Safety of Biotechnology Research and Development further provide that the Ministry of Science and Technology is responsible for national guidance on the safety of biotechnology research and development, and together with the relevant competent departments of the State Council carries out work relating to the safety management of biotechnology research and development, including formulating safety management norms for biotechnology research and development, studying and determining the risk levels of research and development activities, and organizing relevant inspections and guidance.

It should be noted that since 1 May 2024, human genetic resources management work has been transferred from the science and technology departments to the health authorities, and the Ministry of Science and Technology no longer undertakes national responsibilities for administrative licensing, filing, prior reporting and related supervisory enforcement concerning human genetic resources.

3. Drug regulatory department (National Medical Products Administration)

The National Medical Products Administration undertakes, in accordance with law, responsibilities for the research and development, registration, production and post-marketing regulation of drugs and medical devices. For activities involving biological products, drug clinical trials and the research and development of related drugs and medical devices, companies should, in addition to paying attention to biosecurity and human genetic resources regulatory requirements, also perform the corresponding drug or medical device registration, clinical trial and production and operation regulatory obligations in light of the nature of the specific products and research and development activities.

In particular, where there is a regulatory boundary between new biomedical technologies and drugs or medical devices, the relevant research and development entities should reasonably determine the applicable regulatory pathway in accordance with the current definitional rules, so as to avoid errors in determining the regulatory pathway affecting subsequent clinical research and product registration.

4. Customs and other relevant departments

Where human genetic resource materials and other biological materials enter or leave the country, customs, health quarantine and export control regulatory requirements may also be involved at the same time.

For acts of transporting, mailing or carrying China's human genetic resource materials out of the country without permission, the Regulations on the Administration of Human Genetic Resources expressly provide that customs shall handle the matter in accordance with relevant laws and administrative regulations, and the competent human genetic resources department shall provide corresponding law enforcement assistance such as identification in accordance with law. Where special articles for entry and exit are involved, the corresponding approval and declaration procedures shall also be handled in accordance with relevant health quarantine provisions.

02. Analysis of key compliance issues concerning human genetic resources

With the implementation and improvement of laws and regulations such as the Biosecurity Law, the Regulations on the Administration of Human Genetic Resources and their implementing rules, China has established a regulatory system covering activities such as the collection, preservation, utilization and provision abroad of human genetic resources, and administers them through means such as administrative licensing, filing, prior reporting and supervision and inspection.

Where pharmaceutical companies involve China's human genetic resources in the course of drug research and development, clinical trials and cross-border scientific research cooperation, they should determine and perform the corresponding obligations of administrative licensing, filing or prior reporting according to the nature of the specific activities; those violating the relevant provisions may bear administrative liability in accordance with law, and may also bear criminal liability where the constitutive elements under the Criminal Law are met.

Accordingly, relevant companies should establish and improve a human genetic resources compliance management system in light of current regulatory requirements, identify the human genetic resources and related cross-border activities involved in research and development and clinical trials, and adopt corresponding compliance measures according to the nature of different activities. Specifically:

(1) Administrative licensing, filing and prior reporting requirements for human genetic resources

1. Administrative licensing for collection

The administrative licensing for collection of human genetic resources mainly applies to the collection of human genetic resources of important genetic pedigrees and in specific regions carried out within China, and to the collection of human genetic resources for large-scale population research involving more than 3,000 persons.

Under the current regulatory rules, human genetic resource collection activities involved in clinical research conducted to obtain marketing authorization in China for relevant drugs and medical devices do not fall within the scope of collection administrative licensing, provided that they comply with the filing for international cooperative clinical trials or other applicable conditions. Entities applying for administrative licensing for human genetic resource collection shall possess the corresponding subject qualifications in accordance with the law and shall perform ethical review, informed consent and other requirements in accordance with the law.

2. Preservation Administrative Licensing

The administrative licensing for human genetic resource preservation applies to activities conducted within China to preserve human genetic resources and provide a basic platform for scientific research.

The "preservation" of human genetic resources mainly refers to the act of preserving human genetic resources with lawful sources under suitable environmental conditions to ensure their quality and safety for future scientific research. In determining whether a specific preservation activity constitutes preservation, consideration should be given to the purpose and duration of preservation, subsequent scientific research uses, whether it provides a basic platform for scientific research and other actual circumstances; it is not appropriate to determine that no license is required merely under the name of "temporary storage." According to Article 28 of the current Implementing Rules for the Regulations on the Administration of Human Genetic Resources, preservation activities do not include temporary storage for teaching purposes or temporary storage after laboratory testing as required by laws and regulations or agreed in clinical research protocols.

According to the Regulations on the Administration of Human Genetic Resources, foreign organizations, individuals and institutions established or actually controlled by foreign organizations or individuals may not collect or preserve human genetic resources of China within China.

3. Administrative Licensing for International Scientific Research Cooperation

Where foreign organizations and institutions established or actually controlled by foreign organizations or individuals need to use human genetic resources of China to carry out scientific research activities, they shall do so in cooperation with Chinese entities such as Chinese scientific research institutions, institutions of higher education, medical institutions and enterprises.

Where human genetic resources of China are used to carry out international scientific research cooperation, an administrative license for international scientific research cooperation shall in principle be applied for in accordance with the law, and the Chinese entity and its researchers shall be guaranteed substantive participation throughout the entire process, and relevant records and data information during the research process shall be open to the Chinese entity. In practice, whether an international scientific research cooperation is constituted should also be determined by considering factors such as whether the foreign entity substantively participates in the research, whether it accesses or uses human genetic resource materials or information of China, and whether it shares research results. The relevant Q&A published by the National Health Commission in 2025 has further clarified circumstances such as foreign funding, EDC vendors and third-party laboratories.

Both parties to the cooperation shall agree in accordance with the law on the ownership of research results and the distribution of benefits. Where a patent is applied for in respect of results generated from international scientific research cooperation using human genetic resources of China, the application shall be jointly filed by both parties to the cooperation in accordance with the relevant provisions of the Regulations on the Administration of Human Genetic Resources, and the relevant patent rights shall be jointly owned by both parties to the cooperation in accordance with the law.

Projects that meet the conditions for filing of international cooperative clinical trials may, in accordance with relevant provisions, be subject to filing management without the need to apply for an administrative license for international scientific research cooperation.

4. Administrative Licensing for Export of Human Genetic Resource Materials

Where human genetic resources of China are used to carry out international scientific research cooperation, or where human genetic resource materials of China truly need to be transported, mailed or carried out of China under other special circumstances, an administrative license for the export of human genetic resource materials shall be applied for from the National Health Commission in accordance with the law.

Where international scientific research cooperation also involves the export of human genetic resource materials, a separate administrative license for the export of materials may be applied for in accordance with the law, or the relevant export plan may be listed in the application for the administrative license for international scientific research cooperation and handled in accordance with the provisions.

After obtaining the certificate for the export of human genetic resource materials, if the relevant materials also constitute special articles for entry and exit or are subject to other import and export supervision, health quarantine, customs declaration and other procedures shall further be handled in accordance with relevant provisions.

5. Filing of International Cooperative Clinical Trials

For the purpose of obtaining marketing authorization in China for relevant drugs and medical devices, where international cooperative clinical trials using human genetic resources of China are carried out in clinical medical and health institutions, do not involve the export of human genetic resource materials of China, and meet any of the following circumstances, filing management may apply and no administrative license for international scientific research cooperation is required: first, the collection, testing, analysis and disposal of remaining materials of the relevant human genetic resources are all carried out within the clinical medical and health institution; second, collection is carried out within the clinical medical and health institution, and testing, analysis and disposal of remaining samples are carried out by a domestic entity designated in the marketing authorization clinical trial protocol. Projects meeting the above conditions shall, before carrying out the clinical trial, file with the National Health Commission the types, quantities and uses of the human genetic resources to be used.

Particular attention should be paid to the fact that exploratory research portions involved in clinical trials conducted to obtain marketing authorization in China for relevant drugs and medical devices shall require an administrative license for international scientific research cooperation in human genetic resources. Enterprises should distinguish between clinical trial content used for marketing authorization and exploratory research content; for exploratory research content that does not fall within the scope of filing of international cooperative clinical trials but constitutes international scientific research using human genetic resources of China, the corresponding administrative licensing procedures for international scientific research cooperation shall be performed in accordance with the law, and the licensing procedures that should be performed in accordance with the law for the exploratory research portion may not be omitted on the ground that the project has completed clinical trial filing.

International cooperative clinical trials involving the export of human genetic resource materials of China do not apply to the above arrangement of replacing the administrative license for international scientific research cooperation with filing, and the administrative licenses for international scientific research cooperation and for the export of materials shall be handled in accordance with the provisions; where matters such as health quarantine and customs declaration are involved, the corresponding procedures shall also be performed.

6. Prior Reporting for Provision or Open Use of Human Genetic Resource Information to Foreign Parties

Where human genetic resource information of China is provided or made openly available to foreign organizations, individuals and institutions established or actually controlled by foreign organizations or individuals, the Chinese information owner shall, before provision or open use, make a prior report to the National Health Commission in accordance with the law and submit information backup; where the relevant activities may affect public health, national security and public interests of China, a security review shall also be passed in accordance with the law.

Where the conditions stipulated in the current Implementing Rules are met, for projects that have obtained the administrative license for international scientific research cooperation or completed the filing of international cooperative clinical trials, during the implementation of the cooperation, if the international cooperation agreement has agreed that both parties to the cooperation will use the relevant human genetic resource information, the Chinese entity providing such information generated by the cooperation to the foreign entity does not need to separately make a prior report and submit information backup. This exemption applies only to the provision of information meeting the above conditions and should not be extended to circumstances such as providing information to other foreign entities outside the scope of cooperation.

(II) Customs Compliance Requirements for the Entry and Exit of Biological Materials

Where pharmaceutical enterprises are involved in the entry and exit of biological materials, they should first identify whether the relevant materials constitute human genetic resource materials of China and whether they also constitute special articles for entry and exit or are subject to other import and export supervision, and determine the corresponding regulatory requirements separately based on the nature, source and use of the materials.

For the export of human genetic resource materials of China, enterprises shall obtain the administrative license for the export of human genetic resource materials in accordance with the law; if the relevant materials also constitute special articles for entry and exit such as microorganisms, human tissues, biological products, blood and blood products, the corresponding health quarantine approval for special articles for entry and exit and customs declaration procedures shall also be handled in accordance with the Provisions on the Administration of Health Quarantine of Special Articles for Entry and Exit and other norms.

Therefore, enterprises should establish identification and approval processes for entry and exit biological materials based on the source, type, use, recipient and transport method of the biological materials, and verify before actual export whether the scope of approval, types, quantities and uses of materials are consistent with the relevant licenses or approval documents, so as to avoid circumstances of export without license or transport and use of relevant materials beyond the approved scope.

(III) Compliance Requirements for Human Genetic Resource Information and Related Data

The use and cross-border transmission of human genetic resource information may simultaneously be subject to multiple regulatory regimes, including human genetic resource administration, personal information protection and data export.

According to the current rules on human genetic resource administration, where human genetic resource information of China is provided or made openly available to foreign organizations, individuals and institutions established or actually controlled by foreign organizations or individuals, the Chinese information owner shall perform in accordance with the law the obligations of prior reporting and information backup for the provision or open use of human genetic resource information to foreign parties; where the relevant activities may affect public health, national security and public interests of China, a security review shall also be accepted in accordance with the law.

At the same time, where human genetic resource information and other data formed in the course of clinical research also involve personal information, sensitive personal information or important data, the personal information and data export regulatory requirements of the Personal Information Protection Law, the Data Security Law, the Provisions on Promoting and Regulating Cross-Border Data Flows and other rules shall also be complied with.

Enterprises should, based on factors such as data types, processing purposes, foreign recipients, export scale, whether they are operators of critical information infrastructure and whether important data is involved, determine in accordance with the current data export regulatory rules whether the relevant data export activities require declaration of data export security assessment, conclusion of standard contracts for personal information export, passage of personal information export certification, or whether they meet the exemption circumstances under the current provisions.

Where personal information export is involved, the corresponding personal information protection obligations such as notification, obtaining separate consent of individuals and conducting personal information protection impact assessments shall also be performed in accordance with the law.

Particular attention should be paid to the fact that the regulation of human genetic resource information and the regulation of network and data export are relatively independent regulatory systems. The same cross-border data activity may simultaneously trigger requirements relating to human genetic resources and data export. Therefore, for cross-border research projects involving human genetic resource information, enterprises should not understand the completion of procedures such as data export security assessment, standard contracts for personal information export or personal information protection certification as automatically replacing the prior reporting obligation for human genetic resource information, and vice versa.

In addition, the boundary between human genetic resource information and general clinical research data still needs to be identified in specific projects based on data sources and content. According to the current Implementing Rules for the Regulations on the Administration of Human Genetic Resources, human genetic resource information mainly includes information materials such as human gene and genome data generated by using human genetic resource materials, and does not include clinical data, imaging data, protein data and metabolic data.

However, in actual R&D and clinical research activities, different types of data may be combined, associated or further analyzed and processed. Enterprises should still determine whether the relevant data constitutes human genetic resource information based on data sources, specific content, generation methods and processing methods, and further identify the corresponding compliance obligations for human genetic resources and data.

(IV) Compliance Risks Relating to Foreign Investment and Overseas Listing Structures Involving Human Genetic Resources

The current Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition), effective from November 1, 2024, provides that foreign investment is prohibited in the development and application of human stem cells and gene diagnosis and treatment technologies. Pharmaceutical and life science enterprises involved in the restricted fields of the aforementioned negative list should, before introducing foreign investors, implementing cross-border equity transactions or listing overseas, assess the relevant foreign investment access restrictions based on their specific business scope.

Where a domestic enterprise engaged in business in a field prohibited to investment under the Negative List for Foreign Investment Access issues shares and lists them for trading overseas, item 6 of the "Explanatory Notes" to the Negative List provides that it shall be subject to the review and consent of the relevant competent state authorities, overseas investors may not participate in the enterprise's business and management, and their shareholding ratio shall be governed by the relevant provisions on the administration of domestic securities investment by overseas investors. Enterprises shall complete the corresponding procedures in light of the issuance and listing and their control structure, and shall separately comply with the foreign investment access provisions applicable to their business.

At present, specific regional pilot exceptions to the relevant foreign investment access restrictions already exist. In September 2024, the Ministry of Commerce, the National Health Commission and the National Medical Products Administration issued the Notice on Carrying Out Pilot Work to Expand Opening-Up in the Medical Field, permitting qualified foreign-invested enterprises established in the China (Beijing) Pilot Free Trade Zone, the China (Shanghai) Pilot Free Trade Zone, the China (Guangdong) Pilot Free Trade Zone and the Hainan Free Trade Port to engage in the development and application of human stem cell and gene diagnosis and treatment technologies, for product registration, marketing and production. The relevant enterprises shall still comply with China's provisions on the administration of human genetic resources, pharmaceutical clinical trials and drug registration and marketing, drug production, ethical review, and the like.

In addition, for pharmaceutical enterprises with overseas shareholders, overseas listings, or VIE or other contractual control structures, it should further be determined whether they constitute institutions established or actually controlled by foreign organizations or individuals as referred to in the Regulations on the Administration of Human Genetic Resources.

Under Article 12 of the current Implementing Rules for the Regulations on the Administration of Human Genetic Resources, institutions established or actually controlled by foreign organizations or individuals include: institutions in which a foreign organization or individual holds, directly or indirectly, more than 50% of the shares, equity, voting rights, property shares or other similar interests; institutions in which such interests held, directly or indirectly, are less than 50%, but whose voting rights or other interests are sufficient to dominate or exert a material influence over the institution's decision-making, management and other conduct; institutions over which, through investment relationships, agreements or other arrangements, there is sufficient control to dominate or exert a material influence over the institution's decision-making, management and other conduct; and other circumstances provided for by laws, administrative regulations and rules.

Therefore, in determining whether a domestic institution is a foreign party unit, the specific equity structure, voting rights arrangements, contractual control and actual decision-making and management situation should be examined; a conclusion cannot be reached merely on the basis of labels such as "overseas listing" or "VIE structure". Even if the foreign shareholding ratio is less than 50%, as long as the overseas entity, through voting rights, agreements or other arrangements, forms the aforementioned domination or material influence, it may still constitute a foreign party unit. Foreign investment access, overseas issuance and listing, and human genetic resources subject qualification are different regulatory matters; meeting one of these requirements does not automatically satisfy the requirements of the others.

When enterprises raise funds overseas, list, introduce overseas investors or adjust cross-border equity structures, they should simultaneously assess whether the relevant transactions may change the enterprise's subject attributes under the human genetic resources regulatory system, and the resulting impact on their activities such as the collection and preservation of human genetic resources, international cooperation, outbound transfer of materials and provision of information abroad.

03. Review of Typical Cases on Biosafety and Human Genetic Resources

(1) The Ao case of smuggling human genetic resources materials: illegally transporting pregnant women's blood out of the country constitutes a crime

1. Case background

Between August 2020 and September 2023, the defendant Ao and Shen, Zhou and others agreed to jointly smuggle pregnant women's blood to Hong Kong for fetal sex testing and to profit from it. Ao solicited clients by publishing advertisements online and through introductions by relatives and friends; after obtaining the pregnant women's blood provided by clients, he mailed the blood to Shenzhen under the names of daily necessities such as tea leaves and toothpaste, and others then arranged for it to be smuggled to Hong Kong for genetic testing. According to statistics, Ao and others smuggled blood out of the country for 683 person-times in total.

The Intermediate People's Court of Jiangmen City, Guangdong Province, held that Ao, together with others, jointly smuggled pregnant women's blood to Hong Kong for fetal sex testing and profited from it, the circumstances being serious, and that his conduct constituted the crime of smuggling human genetic resources materials. In view of the fact that Ao truthfully confessed the facts of the crime after being brought to justice and voluntarily pleaded guilty and accepted punishment, the court adopted the sentencing recommendation of the procuratorial organ and sentenced Ao to one year's imprisonment for the crime of smuggling human genetic resources materials and imposed a fine of RMB 15,000. Ao accepted the judgment and did not appeal, and the judgment has taken effect.

2. Brief comment

The Amendment (XI) to the Criminal Law took effect on March 1, 2021, and added the crime of illegally collecting human genetic resources and the crime of smuggling human genetic resources materials in Article 334A of the Criminal Law, bringing within the scope of criminal regulation conduct that, in violation of relevant state provisions, illegally collects China's human genetic resources, or illegally transports, mails or carries China's human genetic resources materials out of the country, endangering public health or the public interest and reaching the statutory degree of seriousness.

The establishment of this crime means that the illegal outbound transfer of human genetic resources materials is no longer limited to legal liability at the administrative regulatory level; where the elements of the crime are met, criminal liability may also arise.

The lesson of this case for pharmaceutical R&D enterprises, medical institutions, CROs and related service providers is that enterprises should treat the cross-border transfer of human genetic resources materials as an independent compliance identification matter, and should not handle it directly as ordinary biological sample logistics.

Where cross-border transfer of samples is involved, the relevant entities should first determine whether the samples constitute China's human genetic resources materials, and verify whether the procedures such as administrative licensing for the outbound transfer of human genetic resources materials, health quarantine for special articles of entry and exit, and customs declaration have been completed in accordance with the law, while ensuring that the type, quantity, use and destination of the materials actually transported are consistent with the approved content.

This case also indicates that when enterprises carry out cross-border sample activities, they should not determine the matter merely on the basis of sample names or conventional biological material classifications, but should consider the specific composition of the samples and whether they contain genetic material such as the human genome and genes, in order to determine whether they are materials subject to human genetic resources regulation.

Circumventing human genetic resources and entry-exit regulation through false declaration of product names, ordinary express delivery or other means may not only constitute administrative violations, but may also give rise to criminal legal risk when the statutory threshold is reached.

(2) The human genetic resources administrative licensing case of a certain MNC: entrusting a CRO does not automatically insulate the sponsor from compliance risk

1. Case background

A certain MNC pharmaceutical enterprise, as the sponsor of a clinical study, entrusted a Beijing CRO company to apply for administrative licensing for international cooperation activities involving China's human genetic resources.

In the course of handling the application, relevant personnel of the CRO forged official seals and legal representative signatures and submitted false application materials to the China Human Genetic Resources Administration Office, causing the relevant project to obtain administrative licensing relating to China's human genetic resources through false materials.

On December 20, 2020, the Ministry of Science and Technology made separate penalty decisions: from the date of service of the penalty decision, applications by the CRO company involving international cooperation activities in China's human genetic resources were not to be accepted for one year; and applications by the MNC involving international cooperation activities in China's human genetic resources were not to be accepted for six months.

Public information also shows that the incident simultaneously involved a criminal case. The People's Court of Putuo District, Shanghai, found that from June to July 2018, Lu Moumou, an employee of the CRO company, in order to speed up the process of a research project entrusted for management by the MNC, forged the seals of Zhongshan Hospital Affiliated to Fudan University and of the hospital's medical ethics committee, and used the relevant false documents to apply for human genetic resources administrative licensing. The court ultimately sentenced Lu Moumou to two years' imprisonment with a two-year suspension and a fine of RMB 5,000 for the crime of forging the seal of a public institution.

2. Brief comment

The typical significance of this case is that a clinical trial sponsor's entrusting of specific work such as human genetic resources filing to a CRO or other third party does not mean that the relevant compliance risk is automatically transferred along with the entrustment.

Although the specific material falsification in this case was carried out by CRO staff, the regulatory authorities ultimately took penalty measures against both the CRO and the MNC as the clinical study sponsor. This indicates that when pharmaceutical enterprises use third parties such as CROs to carry out clinical studies and handle human genetic resources-related matters, they should still establish third-party access, entrustment management, application material review and ongoing supervision mechanisms commensurate with the risks, and should not simply rely on the entrusted party to complete the relevant regulatory filings.

It should be noted that the human genetic resources regulatory system on which this case was based at the time has changed from the current rules. Under the current Regulations on the Administration of Human Genetic Resources, for obtaining administrative licensing by providing false materials or other deceptive means, the administrative licensing already obtained may be revoked in accordance with the law, and corresponding legal liability such as fines and refusal to accept licensing applications for a certain period may be borne according to the specific circumstances of the violation. Therefore, under the current regulatory system, the authenticity of human genetic resources administrative licensing application materials and the importance of the project entity's internal review mechanisms are even more prominent.

From the perspective of clinical trial management, the current Good Clinical Practice for Drug Clinical Trials (2026 Revision) further strengthens the sponsor's management responsibility for entrusted clinical trial-related activities. The sponsor may entrust part or all of the clinical trial work tasks to qualified service providers, but shall still exercise appropriate supervision and management over the service providers and the relevant entrusted activities, and bear the corresponding responsibilities under laws and regulations and the Good Clinical Practice for Drug Clinical Trials.

Although the foregoing clinical trial quality management provisions are not the direct legal basis for the human genetic resources administrative penalty in this case, the regulatory logic embodied in the two is consistent: professional work may be entrusted to a third party by contract, but the entrusting party cannot simply transfer its own statutory management, supervision and compliance responsibilities through contractual arrangements. For drug clinical trial sponsor enterprises, business execution may be entrusted, but compliance supervision and risk control cannot simply be outsourced.

*Acknowledgement: Intern Ye Xinmeng (a graduate student in law at Sichuan University) made important contributions to the revision and verification of this article.

Questions and answers

What activities involving human genetic resources require administrative licensing in China?

Administrative licensing is required for collection, preservation, international scientific research cooperation, and export of human genetic resource materials. Collection licensing applies to important genetic pedigrees, specific regions, and large-scale population research involving more than 3,000 persons. Preservation licensing covers activities providing a basic platform for scientific research. International cooperation licensing applies when foreign entities use China's human genetic resources with Chinese partners. Export licensing is needed to transport, mail or carry materials out of China.

When can an international cooperative clinical trial use filing instead of an administrative license for international scientific research cooperation?

Filing applies for clinical trials to obtain marketing authorization in China that use human genetic resources, do not involve export of materials, and meet either of two conditions: all collection, testing, analysis and disposal occur within the clinical medical and health institution; or collection occurs there and testing, analysis and disposal of remaining samples are by a domestic entity designated in the protocol. Exploratory research portions still require an administrative license.

What are the prior reporting obligations for providing human genetic resource information to foreign parties?

The Chinese information owner must, before providing or openly making available human genetic resource information to foreign organizations, individuals or institutions actually controlled by them, make a prior report to the National Health Commission and submit information backup. If the activity may affect public health, national security or public interests, a security review must also be passed. An exemption applies for information generated under an international cooperation license or filed clinical trial where the agreement allows both parties to use it.

What foreign investment restrictions apply to human stem cell and gene diagnosis and treatment technologies?

The Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition), effective November 1, 2024, prohibits foreign investment in the development and application of human stem cells and gene diagnosis and treatment technologies. However, a September 2024 pilot permits qualified foreign-invested enterprises in the China (Beijing), (Shanghai), (Guangdong) Pilot Free Trade Zones and Hainan Free Trade Port to engage in these activities for product registration, marketing and production, subject to compliance with human genetic resources, clinical trial and drug registration rules.

Can a pharmaceutical company avoid compliance responsibility by entrusting human genetic resources filing to a CRO?

No. In a case where a CRO forged seals and submitted false materials, the Ministry of Science and Technology penalized both the CRO and the multinational sponsor, refusing applications for one year and six months respectively. Entrusting work to a CRO does not transfer compliance risk. Sponsors should establish third-party access, entrustment management, application material review and ongoing supervision mechanisms, and cannot simply rely on the entrusted party.

Laws and cases cited

Laws

  • Biosecurity Law
  • Law on the Prevention and Control of Infectious Diseases
  • Drug Administration Law
  • Vaccine Administration Law
  • Frontier Health Quarantine Law
  • Civil Code
  • Personal Information Protection Law
  • Data Security Law
  • Criminal Law

Regulations

  • Regulations on the Biosafety Management of Pathogenic Microorganism Laboratories
  • Regulations on the Management of Human Genetic Resources
  • Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies
  • Implementing Regulations of the Drug Administration Law

Policy documents

  • Announcement on Strengthening the Supervision and Administration of Entrusted Production by Drug Marketing Authorization Holders (No. 132 of 2023)
  • Announcement on Strengthening the Supervision and Administration of Entrusted Production by Contracted Manufacturers (No. 134 of 2025)

References

  1. National Health Commission: Announcement on the Adjustment of Human Genetic Resources Management Work, April 25, 2024.
  2. Ministry of Science and Technology: Announcement on the Adjustment of Responsibility for Human Genetic Resources Management from the Ministry of Science and Technology to the National Health Commission, April 25, 2024.
  3. National Health Commission: Announcement of the National Health Commission — Matters Concerning the Adjustment of the Review of the Construction of High-Level Pathogenic Microorganism Laboratories, January 20, 2025.
  4. National Health Commission and National Disease Control and Prevention Administration: Announcement on Matters Concerning the Implementation of the Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies (No. 4 of 2026), April 30, 2026.
  5. Ministry of Science and Technology: Measures for the Safety Management of Biotechnology Research and Development (Guo Ke Fa She [2017] No. 198), July 12, 2017.
  6. National Medical Products Administration: Announcement on Strengthening the Supervision and Administration of Entrusted Production by Marketing Authorization Holders (No. 132 of 2023), October 17, 2023.
  7. National Medical Products Administration: Announcement on Strengthening the Supervision and Administration of Entrusted Drug Production (No. 134 of 2025), December 30, 2025.
  8. National Health Commission: Service Guidelines for Administrative Licensing Matters Concerning Human Genetic Resources, and the Scope and Procedures for Filing and Prior Reporting, March 20, 2025.
  9. Department of Science, Technology and Education of the National Health Commission: Notice on Issuing the Frequently Asked Questions on the Administration of Human Genetic Resources, March 27, 2025.
  10. Department of Science, Technology and Education of the National Health Commission: Announcement on Public Consultation on the Implementing Rules for the Regulations on the Administration of Human Genetic Resources (Draft for Comment), May 8, 2026.
  11. Cyberspace Administration of China: Provisions on Promoting and Regulating Cross-Border Data Flows (Order No. 16 of the Cyberspace Administration of China), March 22, 2024.
  12. Cyberspace Administration of China and State Administration for Market Regulation: Measures for Certification of Personal Information Export, October 14, 2025, effective January 1, 2026.
  13. National Development and Reform Commission and Ministry of Commerce: Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition) (Order No. 23), September 6, 2024.
  14. Ministry of Commerce, National Health Commission and National Medical Products Administration: Notice on Carrying Out Pilot Programs for Expanding Opening-Up in the Medical Field (Shang Zi Han [2024] No. 568), September 7, 2024.
  15. People's Court Daily: A Defendant in Guangdong Sentenced for the Crime of Smuggling Human Genetic Resource Materials, February 18, 2025.
  16. Ministry of Science and Technology: Administrative Penalty Decision (Guo Ke Fa [2020] No. 1), December 20, 2020.
  17. Ministry of Science and Technology: Administrative Penalty Decision (Guo Ke Fa [2020] No. 2), December 20, 2020.
  18. Shanghai Putuo District People's Court: First-Instance Criminal Judgment in the Case of Lu Moumou Forging the Seals of Companies, Enterprises, Institutions and People's Organizations (2020) Hu 0107 Xing Chu No. 163.
  19. National Medical Products Administration, National Health Commission, National Administration of Traditional Chinese Medicine and National Disease Control and Prevention Administration: Announcement on Issuing the Good Clinical Practice for Drug Trials (No. 50 of 2026), May 21, 2026 (effective September 1, 2026).
  20. Standing Committee of the National People's Congress: Biosecurity Law of the People's Republic of China, adopted October 17, 2020, amended April 26, 2024, effective April 15, 2021.
  21. State Council: Regulations of the People's Republic of China on the Administration of Human Genetic Resources, promulgated May 28, 2019, revised in accordance with the Decision of the State Council on Amending and Repealing Certain Administrative Regulations of March 10, 2024.
  22. Ministry of Science and Technology: Implementing Rules for the Regulations on the Administration of Human Genetic Resources (Order No. 21 of the Ministry of Science and Technology), promulgated May 26, 2023, effective July 1, 2023.
  23. State Council: Regulations on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies (Order No. 818 of the State Council), promulgated September 28, 2025, effective May 1, 2026.
  24. National Health Commission: Notice on Issuing the Guiding Principles (Interim) for Distinguishing New Biomedical Technologies from Drugs and Medical Devices, April 28, 2026.
  25. State Council: Implementing Regulations of the Drug Administration Law of the People's Republic of China (Order No. 828 of the State Council), promulgated January 16, 2026, effective May 15, 2026.